The VALOR Study – A Clinical Trial for People Living with SOD1-ALS

Biogen is conducting a clinical trial to evaluate the safety and potential…

Words Lucie van Leeuwen.Published October 6, 2020
The VALOR Study – A Clinical Trial for People Living with SOD1-ALS

Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) carrying a SOD1 gene mutation.

Update 31-12-2021: Please note that the study is now active and enrolment is completed.

Study Duration

  • 32-36 weeks, including:
  • 4-week screening
  • 24-week study treatment period
  • 4 to 8-week follow-up period

Investigational Drug

  • Tofersen (BIIB067), an antisense oligonucleotide (ASO)
  • Designed to reduce the amount of SOD1 protein in the body
  • Given intrathecally, through a lumbar puncture

Key Eligibility Criteria

  • 18 years of age or older
  • Have weakness caused by ALS
  • Agree to genetic testing for the SOD1 mutation

All Eligible Participants Will Receive At No Cost

  • Comprehensive study-related health evaluations and assessments, including genetic testing
  • Investigational drug or placebo
  • All study-related visits and care

Assistance with travel and accommodations, and reimbursement for study-related expenses may also be available. See if you may be eligible and view our study locations.


Share

Related news

Newsletter December 2020
Newsletter December 2020
2020 has been a difficult year for everyone. However, despite the many […]
Reconsidering the ALSFRS-R for ALS clinical trials
Reconsidering the ALSFRS-R for ALS clinical trials
Questionnaires, such as the ALS Functional Rating Scale (ALSFRS), play an important […]
Summary of the 31st International Symposium on ALS/MND
Summary of the 31st International Symposium on ALS/MND
Last week the 31st International Symposium on ALS/MND was held online. This […]
Summary ENCALS Satellite meeting
Summary ENCALS Satellite meeting
In the run-up to the virtual 31st International Symposium on ALS/MND, the […]